BRPA

RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

4/A - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (NASDAQ:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no curr

25-NSE - Big Rock Partners Acquisition Corp. (0001719406) (Subject)

25-NSE - Big Rock Partners Acquisition Corp. (0001719406) (Subject)

EFFECT - Big Rock Partners Acquisition Corp. (0001719406) (Filer)

Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (NASDAQ:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.Big Rock also announced that the U.S. Securities and Exchange Commission has declared effective its registration state

424B3 - Big Rock Partners Acquisition Corp. (0001719406) (Filer)

S-4/A - Big Rock Partners Acquisition Corp. (0001719406) (Filer)

S-4/A - Big Rock Partners Acquisition Corp. (0001719406) (Filer)

NT 10-Q - Big Rock Partners Acquisition Corp. (0001719406) (Filer)

425 - Big Rock Partners Acquisition Corp. (0001719406) (Subject)

8-K - Big Rock Partners Acquisition Corp. (0001719406) (Filer)

RADNOR, Pa. and TBLISI, Georgia, April 28, 2021 /PRNewswire/ -- NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its phase 3 drug, ZYESAMI (aviptadil acetate) for critically-ill citizens of Georgia with COVID-19 Respiratory Failure.  The EAP will be conducted in collaboration with Denk Pharma Georgia, Georgia's primary pharmaceutical distributor, and under the auspices of the Potomac Institute of Policy Studies and the Richard G. Lugar Center for Public Health Research, a research facility funded by the U.S. Defense Threat Reduction Agency and named in

RADNOR, Pa., April 26, 2021 /PRNewswire/ -- Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO) (www.clinicaltrials.gov NCT04843761), will study ZYESAMI to treat severely ill COVID-19 patients. The study will be carried out across the United States as part of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to prioritize and accelerate development of the most promising COVID-19 treatments. NeuroRx is designated by NIH as an industry partne

8-K - Big Rock Partners Acquisition Corp. (0001719406) (Filer)

425 - Big Rock Partners Acquisition Corp. (0001719406) (Subject)